Core Viewpoint - Zhejiang Bangjie Holdings Group Co., Ltd. and its subsidiary, Yangzhou Bangjie New Energy Technology Co., Ltd., are undergoing a pre-restructuring process due to financial difficulties, initiated by a creditor's application for bankruptcy restructuring [2][6]. Group 1: Bankruptcy Restructuring Process - On September 4, 2025, the company disclosed that Yangzhou Bangjie received a notice from the court regarding a creditor's application for pre-restructuring due to its inability to repay debts [2]. - The court accepted the pre-restructuring application on September 16, 2025, and appointed a management team for the restructuring process on November 18, 2025 [2][3]. - The court officially accepted the restructuring application on January 30, 2026, but has not yet appointed a manager for the process [3][6]. Group 2: Financial Obligations and Risks - Yangzhou Bangjie has a financial liability exposure of approximately 630 million yuan, with all financial liabilities guaranteed by the company, posing a risk of fulfilling these obligations [10]. - The company has invested 505 million yuan directly and indirectly in Yangzhou Bangjie, which may lead to risks of unrecoverable investments due to the restructuring [10]. - The company is also a significant creditor, having provided around 650 million yuan in financial support to Yangzhou Bangjie, which may result in risks of uncollectible receivables [11]. Group 3: Impact on Business Operations - Yangzhou Bangjie is a core subsidiary and an important operational platform for the company's photovoltaic business; successful restructuring could improve the company's financial structure [10]. - The ongoing restructuring process may negatively impact the company's seamless clothing business, which has historically generated significant revenue [14]. - The company is closely monitoring the restructuring developments and will disclose relevant information as required [14].

Core Viewpoint - The company plans to utilize idle self-owned funds for cash management to enhance fund efficiency and increase returns for the company and its shareholders [3][9]. Group 1: Cash Management Details - The company intends to invest up to RMB 30 million (maximum daily balance, including this amount) in cash management products [3][6]. - The investment period for the cash management will not exceed 12 months from the date of board approval [5][6]. - The source of funds for this cash management is the company's idle self-owned funds [4]. Group 2: Approval Process - The company held meetings on December 29, 2025, where the board's audit committee and independent directors approved the cash management proposal, which does not require shareholder approval [2][6]. - The sponsor, ShenGang Securities Co., Ltd., provided a non-objection opinion on this matter [2][6]. Group 3: Investment Purpose and Strategy - The purpose of the investment is to improve the efficiency of idle funds without affecting daily operational funds and ensuring fund safety [3][9]. - The company will select financial products that are high in safety, good in liquidity, and low in risk for cash management [2][7]. Group 4: Impact on Company - The cash management will not affect the company's main business development and is expected to enhance the efficiency of fund usage and cash asset returns, benefiting all shareholders [9].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●中船科技股份有限公司（以下简称"公司"）关联股东中国船舶集团重庆船舶工业有限公司（以下简 称"重庆船舶工业"）、重庆川东船舶重工有限责任公司（以下简称"川东船舶重工"）分别与公司关联股 东中国船舶集团投资有限公司（以下简称"中船投资公司"）签署《股份转让协议》，重庆船舶工业拟通 过协议转让方式向中船投资公司转让21,910,000股，川东船舶重工拟通过协议转让方式向中船投资公司 转让1,978,774股，合计23,888,774股，占公司总股本的1.59%（以下简称"本次股份转让"）。 ●2023年8月，公司完成重大重组事项，并与中国船舶重工集团有限公司及其他具有关联关系的交易方 签署了《盈利预测补偿协议》及补充协议（以下简称"补偿协议"，具体内容可详见公司于2023年7月8日 在上海证券交易所披露的《中船科技股份有限公司发行股份及支付现金购买资产并募集配套资金暨关联 交易报告书》），业绩承诺方对本次重组相关标的公司业绩情况进行了相应承诺，业绩承诺期为标的公 司 ...

Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. has received a confirmation letter from the FDA regarding the acceptance of its Biologics License Application (BLA) for injection of Carrelizumab combined with Apatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma patients, with a target review date set for July 23, 2026 [1][2]. Group 1: Drug Information - Drug Name: Injection of Carrelizumab [1] - Dosage Form: Injection [1] - Applicant: Jiangsu Hengrui Medicine Co., Ltd. [1] - Indication: First-line treatment for unresectable or metastatic hepatocellular carcinoma in combination with Apatinib [1]. Group 2: Clinical Trial Information - The international multicenter Phase III clinical trial (Study No. SHR-1210-III-310) for Carrelizumab combined with Apatinib was approved in December 2018 [2]. - The trial demonstrated that Carrelizumab combined with Apatinib significantly extended progression-free survival (PFS) and overall survival (OS) compared to Sorafenib [2][3]. - The study enrolled 543 participants and showed a median PFS of 5.6 months and a median OS of 22.1 months, with the final analysis indicating an OS extension to 23.8 months [3]. Group 3: Market Context - Carrelizumab is a humanized anti-PD-1 monoclonal antibody that restores the body's anti-tumor immunity [5]. - The global sales of anti-PD-1 antibodies are projected to reach approximately $41.546 billion in 2024 [5]. - Cumulative R&D investment for Carrelizumab has reached approximately 319.74 million yuan (unaudited) [5].

证券代码：600392 证券简称：盛和资源 公告编号：临2026-003 公司对ETM的上述观点不予认可。下一步，公司将积极与ETM公司保持沟通交流，采取法律手段全力 维护自身合法权益。 经初步评估，上述事项预计不会对公司产生重大影响。一方面，公司对ETM公司累计投资金额2,434.57 万元，根据企业会计准则，公司对ETM公司的投资列报为其他权益工具投资（以公允价值计量且变动 计入其他综合收益），截至2025年9月30日，公司持有ETM公司股权较初始投资累计实现公允价值增值 并计入其他综合收益金额折算人民币约为1,722万元。另一方面，截至目前ETM公司所属科瓦内湾 (Kvanefijeld)稀土项目尚未取得采矿权证，该公司尚未从事实质性生产经营活动，不会对公司业务造成 负面影响。 特此公告。 盛和资源控股股份有限公司（以下简称"公司"）于2016年9月23日发布公告：本公司以及控股子公司乐 山盛和稀土股份有限公司（以下简称"乐山盛和"）与格陵兰矿物能源有限公司（以下简称"格陵兰公 司"）签署《格陵兰矿物能源有限公司和乐山盛和稀土股份有限公司以及盛和资源控股股份有限公司股 份认购协议》(以下简称"《股份认购 ...

Core Viewpoint - The stock of Anhui Jinzhongzi Liquor Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative closing price increase of 20% over three consecutive trading days, prompting the company to clarify its operational status and financial outlook [2][5]. Group 1: Stock Trading Abnormality - The company's stock price increased by a cumulative 20% over three trading days: January 29, January 30, and February 2, 2026, which is classified as an abnormal trading fluctuation according to Shanghai Stock Exchange regulations [2][5]. - The company disclosed a pre-loss announcement for the year 2025, projecting a net profit attributable to shareholders of the parent company to be between -190 million and -150 million yuan, and a net profit after deducting non-recurring gains and losses to be between -210 million and -170 million yuan [2][10]. Group 2: Company Verification and Operational Status - The company conducted a self-examination and confirmed that its production and operations are normal, with no significant changes in market conditions or industry policies that would affect stock price fluctuations [6]. - There are no undisclosed significant matters that could impact the company's stock price, including major asset restructuring, share issuance, or other significant transactions [7]. - The company found no media reports or market rumors that could significantly affect its stock price [8]. Group 3: Board of Directors' Statement - The board of directors confirmed that there are no undisclosed matters that should have been disclosed according to stock listing rules, and previous disclosures do not require correction or supplementation [11].

证券代码：600246 证券简称：万通发展 公告编号：2026-011 北京万通新发展集团股份有限公司 关于2025年限制性股票激励计划首次授予结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 一、股权激励计划前期基本情况 北京万通新发展集团股份有限公司（以下简称"公司"）2025年限制性股票激励计划（以下简称"本次激 励计划"）方式为限制性股票，股份来源为向激励对象定向发行公司人民币A股普通股股票，拟授予的 权益数量为94,520,624股，占公司总股本比例为5%。其中，首次授予的权益数量为79,397,324股，占公 司总股本比例为4.2%；预留授予的权益数量为15,123,300股，占公司总股本比例为0.8%。具体内容详见 公司2025年11月18日披露于上海证券交易所官网（www.sse.com.cn）的《北京万通新发展集团股份有限 公司2025年限制性股票激励计划（草案）摘要公告》（公告编号：2025-086）。 二、限制性股票授予情况 （一）本次权益实际授予的具体情况 ■ 根据《上市公司 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600819 证券简称：耀皮玻璃 公告编号：2026-014 900918 耀皮B股 上海耀皮玻璃集团股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 已履行的审议程序：上海耀皮玻璃集团股份有限公司（以下简称"公司"）于2026年1月26日召开第十 一届董事会第十五次会议，审议通过了《关于使用部分暂时闲置募集资金进行现金管理的议案》，同意 使用最高额度不超过人民币2.80亿元的部分暂时闲置募集资金进行现金管理，投资安全性高、流动性 好、单项产品投资期限不超过12个月的投资产品。使用期限不超过12 个月，自本次董事会审议通过之 日起 12 个月之内有效。保荐人国泰海通证券股份有限公司（以下简称"保荐人"）对上述事项出具了明 确的核查意见。具体内容详见《上海耀皮玻璃集团股份有限公司关于使用部分闲置募集资金进行现金管 理的公告》（公告编号：2026-012）。 ● 特别风险提示：公司本次购买的结构性 ...

Core Viewpoint - Anhui Construction Group Co., Ltd. announced a cash dividend distribution plan for the first three quarters of 2025, with a cash dividend of 0.1 yuan per share, totaling approximately 171.65 million yuan [2][4]. Distribution Plan - The cash dividend distribution is based on a total share capital of 1,716,533,938 shares, resulting in a total cash dividend payout of 171,653,393.80 yuan [4]. - The distribution will be made to all shareholders registered with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the day before the equity registration date [3]. Implementation Details - The cash dividends will be distributed through the clearing system of China Securities Depository and Clearing Corporation Limited, with shareholders who have completed designated transactions able to receive their dividends on the payment date [5]. - The distribution does not involve the issuance of bonus shares or capital increases [6]. Taxation Information - For individual shareholders holding unrestricted circulating shares, dividends are subject to different tax treatments based on the holding period, with a maximum tax rate of 20% for shares held for one month or less, and a 10% rate for shares held between one month and one year [8][9]. - For Qualified Foreign Institutional Investors (QFII), a 10% withholding tax will be applied, resulting in a net cash dividend of 0.09 yuan per share [9]. - Hong Kong Stock Exchange investors will also receive a net cash dividend of 0.09 yuan per share after a 10% withholding tax [9]. Contact Information - For inquiries regarding the dividend distribution, shareholders can contact the company's securities affairs department at 0551-62865300 [11].

Core Viewpoint - The company has provided guarantees for its subsidiaries to support their operational needs, involving significant financial commitments and internal approvals [1][2][3]. Group 1: Guarantee Details - The company signed a maximum pledge contract and a margin guarantee contract with Zhejiang Zheshang Bank to provide a pledge guarantee for a total debt principal of 11.1965 billion HKD for its subsidiary [1]. - The company has approved a total guarantee limit of up to 203 billion CNY for 31 subsidiaries and 65 billion CNY for 5 joint ventures and associates, with the guarantees expected to be valid for twelve months from the approval date [2]. - The total external guarantees approved by the company and its subsidiaries amount to 325.72 billion CNY, with guarantees to subsidiaries totaling 203 billion CNY, representing 77.74% of the company's latest audited net assets [3]. Group 2: Decision-Making Process - The decision to provide guarantees was made after a comprehensive analysis of the subsidiaries' profitability, debt repayment ability, and associated risks, ensuring that the guarantees are within a controllable risk range [3]. - The board of directors unanimously approved the proposal to provide guarantees for subsidiaries, indicating strong internal consensus on the decision [3]. Group 3: Current Guarantee Status - As of now, the company has signed guarantee contracts amounting to 245.25 billion CNY, which is 58.54% of the company's latest audited net assets, with no overdue external guarantees reported [3].